Prime Medicine Reports $1.2M Revenue in Q3 2025, Net Loss of $50.6M

Prime Medicine, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $1.2 million, a significant increase from $209,000 in the same period last year. The revenue for the nine months ended September 30, 2025, reached $3.8 million, compared to $800,000 for the same period in 2024. The increase in revenue was primarily attributed to collaboration revenue from related parties, which amounted to $1.2 million for the quarter and $3.7 million for the nine months. Despite this growth in revenue, the company continued to experience substantial operating losses, reporting a net loss of $50.6 million for the third quarter, slightly improved from a loss of $52.5 million in the prior year. For the nine-month period, the net loss was $155.1 million, compared to $153.6 million in 2024.

In terms of operational developments, Prime Medicine has made strategic advancements in its research and development efforts, particularly in its in vivo liver franchise targeting Wilson’s Disease and Alpha-1 Antitrypsin Deficiency (AATD). Both programs are in late preclinical stages, with plans for Investigational New Drug (IND) filings in the first half of 2026. The company also reported progress in its Phase 1/2 trial for chronic granulomatous disease (CGD), with promising results from initial patient dosages. The company’s workforce has been adjusted, resulting in a reduction of personnel expenses, which decreased by $4 million in the third quarter compared to the previous year.

Prime Medicine's total assets as of September 30, 2025, were reported at $385 million, up from $297.5 million at the end of 2024. This increase was driven by a substantial rise in cash and short-term investments, which totaled $231.4 million, compared to $211.9 million at the end of the previous year. The company’s liabilities also increased, totaling $223.2 million, up from $144.4 million, largely due to an increase in operating lease liabilities and research and development funding liabilities. The company’s stockholders’ equity rose to $161.8 million, reflecting the issuance of 43.7 million shares in an August 2025 public offering, which generated approximately $138.4 million in net proceeds.

Looking ahead, Prime Medicine anticipates continued operating losses as it advances its research and development programs. The company expects its existing cash and investments will be sufficient to fund operations for at least the next twelve months. However, it acknowledges the need for additional capital to support ongoing research, development activities, and potential commercialization efforts. The company plans to explore various funding avenues, including public and private equity offerings, collaborations, and strategic partnerships, to bolster its financial resources and support its growth strategy.